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The interaction between antithrombin 111 (ATIII) and albu- 
min-heparin conjugates covalently coupled onto carboxyl- 
ated polystyrene beads either in buffer containing albumin 
or in plasma was studied using I4C-labeled ATIII. Binding 
isotherms of ATIII were modeled using a summation of two 
Langmuir equations. These equations describe the binding 
of AT111 to two different sets of binding sites, one with a 
high, the other with a low affinity for ATIII. The average 
bindin constants for the binding of ATIII to these sites are 
ing of ATIII to surface binding sites with a high affinity for 
ATIII was correlated with the presence of specific ATIII 
binding sites in the immobilized heparin. Binding of ATIII 
from albumin solutions to binding sites with a low affinity 
for ATIII was dominated by nonspecific binding of ATIII to 
the immobilized heparin. A third small fraction of the sur- 
face bound ATIII is probably adsorbed to sites on the sur- 
face not covered with heparin. In the case of the binding of 
9 x 10 i5 Limol and 0.3 x lo6 Limol, respectively. The bind- 
ATIII to the heparinized surface from plasma solutions, a 
fraction of initially adsorbed ATIII was desorbed by other 
plasma proteins. This desorption in combination with di- 
rect competition between ATIII and other plasma proteins 
resulted in lower ATIII surface concentrations using plasma 
as compared to the ATIII surface concentrations obtained 
using albumin solutions. The binding of ATIII to nonspe- 
cific binding sites was almost completely inhibited in the 
presence of plasma proteins. The amount of ATIII bound to 
immobilized heparin via specific ATIII binding sites was 
30% lower in plasma solutions as compared to the specific 
binding of ATIII using albumin solutions. It is concluded 
that the accessibility of immobilized heparin for ATIII in 
plasma decreases by binding of heparin-binding proteins 
onto the immobilized heparin and/or by adsorption of other 
plasma proteins on the heparinized surface. 0 1995 John 
Wiley & Sons, Inc. 
INTRODUCTION 
Heparin frequently has been applied for the mod- 
ification of polymeric surfaces.’-5 The covalent immo- 
bilization of heparin onto a biomaterial surface usu- 
ally results in a stable heparin coating that exerts an- 
ticoagulant activity if the immobilized heparin 
molecules are sufficiently mobile and accessible for 
antithrombin I11 (ATIII) and clotting proteins.2p6t7 
One-third of heparin molecules in commercially 
available unfractionated heparin contains a pentasac- 
charide sequence with a high affinity for ATIII.8 For 
the potentiating effect of heparin on ATIII in the in- 
hibition of clotting proteases, it is essential that ATIII 
be bound to heparin via this specific binding site. 
Other plasma proteins, such as histidine-rich glyco- 
protein (HRGP),9-11 platelet factor four,” and vit- 
ronectin,13 also bind to heparin and thereby revers- 
ibly neutralize its action, probably by competition 
“To whom correspondence should be addressed. 
with ATIII and clotting proteases, for binding to the 
negatively charged mucopolysaccharide.14~15 
It is well known that when a biomaterial is brought 
into contact with blood or plasma, usually protein 
adsorption onto the surface will take place. When a 
surface contains covalently bound heparin, the ques- 
tion arises as to how the interaction of immobilized 
heparin with ATIII is influenced by the presence of 
other plasma proteins. 
In this study we have focused on the interaction of 
ATIII with a well-defined and characterized heparin- 
containing surface. This surface was obtained by the 
modification of carboxylated polystyrene beads with 
covalently bound albumin-heparin (alb-hep) conju- 
gates. A coating consisting of albumin and heparin 
combines the beneficial effects of surface-bound hep- 
arin with passivation of the surface with an albumin 
layer. When Hennink et al. studied the interaction of 
ATIII with a polystyrene substrate preadsorbed with 
albumin-heparin conjugates,16 the highest amounts 
of antithrombin 111 were bound by surfaces modified 
with alb-hep conjugates with a high affinity for 
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ATIII. It was concluded that the interaction of ATIII 
with the alb-hep-conjugates-coated surfaces takes 
place via the heparin moiety of the conjugate. 
Hypothetically, three types of interactions between 
ATIII and a heparinized surface can be distinguished. 
The first one is a specific interaction between ATIII 
and ATIII binding sites on the surface-immobilized 
heparin. ATIII molecules also can bind to the immo- 
bilized heparin via nonspecific binding sites. The 
third type of interaction involves the adsorption of 
ATIII on surface areas not covered with heparin. Pa- 
rameters that influence these interactions are the na- 
ture and immobilization method of heparin, includ- 
ing the use of spacers, the nature of the material sur- 
face, and the medium used for the ATIII adsorption, 
especially the presence or absence of other (heparin- 
binding) proteins. 
This study is to elucidate the interactions between 
ATIII and polystyrene surfaces coated with co- 
valently immobilized alb-hep conjugates with differ- 
ent affinities for ATIII. The nature and the contribu- 
tion of the different interactions of ATIII with the 
heparinized surfaces in both a buffer system contain- 
ing albumin and in plasma were investigated. 
MATERIALS AND METHODS 
Labeling and purification of ATIII 
Human ATIII was supplied by the Dutch Red Cross 
Blood Transfusion Service, Amsterdam, The Nether- 
lands. The lyophilized material (5.2 U/mg) contained 
+5% immunoglobulin (IgG) against hepatitis. The 
ATIII was labeled by reductive methylation using 
''C-formaldehyde (27.2 mCiimmole, Amersham, UK) 
in the presence of NaCNBH,I7 (Merck, Darmstadt, 
Germany). In a typical labeling experiment, 100 mg 
ATIII was reconstituted with 5 mL distilled water. 
''C-formaldehyde (125 pCi) was added under light 
stirring. Aliquots of 100 pL NaCNBH, (1 g/L) were 
added every 15 min for 3 h. The labeled ATIII was 
purified on a heparin-Sepharose column'8 (792 pg 
heparin/mL gel, Sigma, St Louis, USA). The heparin- 
Sepharose was washed with a NaH,PO,/Na,HPO, 
buffer (12.5 mM, pH 7.4) containing 1.8 M NaCl be- 
fore use to remove unbound heparin. The column 
was equilibrated with PBS pH 7.4, after which the 
reaction mixture was applied on the column. The col- 
umn was eluted with a NaH,P04/Na,HP04 buffer 
(12.5 mM, pH 7.4) initially containing 0.4 M NaC1, 
which was increased to 1.8 M NaC1. The protein con- 
tent of the eluent continuously was monitored with a 
spectrophotometer (UV1 LKB, Uppsala, Sweden) at 
280 nm. The radioactivity of the eluent was measured 
using samples obtained after different elution times. 
The radioactivity was determined with a scintillation 
counter (1219 Rackbeta, LKB-Wallac Turku, Finland) 
using a mixture of 2 mL LumaSolve, 18 mL LumaGel 
(Lumac LSC, Olen, Belgium) and 200 pL 6 N HC1. 
ATIII fractions were pooled and dialyzed against dis- 
tilled water and PBS at 4°C. The protein content was 
measured using Coomassie Plus Protein Reagent 
(Pierce, Rockford, USA) at 595 nm. The incorporation 
of label resulted in a specific activity between 1600- 
2100 CPMlpg protein. The purity of the starting ma- 
terial and the ATIII fractions obtained after purifica- 
tion were studied using SDS gel electrophoresis 
(Phast System LKB, Uppsala, Sweden). 
Characterization of 14C-labeled ATIII 
The biological activity of labeled ATIII was com- 
pared to that of unlabeled ATIII in an endpoint 
thrombin inhibition assay using a chromogenic sub- 
strate (S 2238, Kabi Vitrum, Stockholm, Sweden)." 
To detect any change in binding between ATIII and 
heparin upon labeling, labeled and unlabeled ATIII 
were eluted on a heparin-Sepharose column using a 
NaCl gradient ranging from 0.15-1.8 mol/L in a 
NaH,PO,/Na,HPO, buffer (12.5 mM pH 7.4). 
Preferential binding of labeled ATIII on a surface 
containing covalently coupled alb-hep conjugates 
was investigated by mixing labeled and unlabeled 
ATIII in different ratios to a final concentration of 150 
pgimL. The ATIII mixtures, dissolved in PBS pH 7.4, 
containing 40 mg/mL albumin, were exposed to the 
heparinized surface for 1 h at 37°C. After incubation 
the beads were washed 3 times with PBS, transferred 
into a scintillation vial containing 2 mL LumaSolve, 
and incubated for 1 h at 55°C to dissolve the ATIII. 
After the vials were cooled, 18 mL LumaGel and 200 
pL 6 N HC1 were added. The radioactivity was mea- 
sured and plotted against the ratio of labeled and 
unlabeled ATIII. 
Preparation of plasma containing labeled ATIII 
Eluted at high ionic strength in the purification pro- 
cedure, and thus having a high affinity for heparin, 
I4C-labeled ATIII was added to ATIII-free plasma to a 
final concentration of 130 pg/mL. ATIII-free plasma 
was prepared by mixing 80 mL of citrated fresh fro- 
zen human plasma with 50 mL heparin-Sepharose 
for 15 min at 4°C. The heparin-Sepharose was re- 
moved from the plasma by filtration using a fritted 
glass filter with a pore size of 20 pm. The clear plasma 
filtrate was considered to be ATIII-free, based on a 
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thrombin inhibition assay in which no ATIII activity 
could be detected. A drawback of this depletion pro- 
cedure is that in addition to ATIII, probably other 
heparin-binding proteins are removed or their con- 
centrations decreased. Aliquots of 1 mL of labeled 
ATIII in both PBS and plasma were snapfrozen at 
- 80°C and stored at - 30°C. 
Preparation and characterization of 
albumin-heparin surfaces 
Carboxylated polystyrene (PS) beads (diameter 
0.918 pm ? 0.020 pm, 0.12 meq COOH/g) were pur- 
chased from Polysciences Inc., Warrington, U.S. A. 
Albumin-heparin conjugates, based on bovine albu- 
min, were purchased from Holland Biomaterials 
Group BV, Enschede, The Netherlands. The heparin 
contents of these conjugates were 14.5, 16.5, and 
21.5% (w/w). These conjugates differ in their affinity 
for ATIII and are further referred to as Low Affinity 
(LA), Unfractionated (Un) and High Affinity (HA) 
alb-hep conjugates, respectively. Bovine albumin 
(Sigma) was treated with N-(3-dimethylamino- 
propy1)-N'-ethylcarbodiimide (EDC, Merck, Darm- 
stadt, Germany) analogous to reaction conditions 
used for the preparation of the alb-hep conjugates.20 
In short, albumin was added to a NaH,PO, solution 
of pH 4.4 and dissolved overnight at 4°C. EDC was 
added in aliquots over a period of 3.5 h to a total of a 
10 times molar excess over albumin. In contrast with 
the alb-hep conjugates EDC-treated albumin was not 
chromatographically purified but was dialyzed 
against water and freeze dried. EDC-treated albumin 
and untreated bovine albumin were used as controls 
throughout the experiments and henceforth will be 
referred to as Alb-EDC and Alb, respectively. 
Alb-hep conjugates were immobilized onto the car- 
boxylated polystyrene beads via preactivation of the 
surface with EDC. Before immobilization the beads 
were washed once with a NaHC03/Na2C0, buffer 
(0.1 M, pH 9.6) and twice with a NaH2P04 buffer 
(0.02 M, pH 4.5) and then suspended in the same 
phosphate buffer. Aliquots of 100 pL of EDC solution 
dissolved in distilled water were added every 10 min 
to the suspension of the beads during one h. The total 
of moles of EDC present was 60% of that of the avail- 
able carboxyl groups. The beads were centrifuged 
and resuspended in an alb-hep conjugate solution in 
borate buffer 0.1 M, pH 8.4 and stirred overnight at 
room temperature. The alb-hep conjugates were 
checked with Coomassie Plus Protein Reagent. The 
beads were resuspended in PBS containing 0.02% 
azide and stored at 5°C. 
Beads containing immobilized albumin-heparin 
conjugates (alb-hep beads) were characterized using 
a tolui'dine blue assay to determine the heparin sur- 
face concentration.21 Appropriate amounts of a tolu- 
i'dine blue solution (0.1 g/L, 2% w/w NaC1, pH 2) 
were added to heparin reference samples (168.5 
Uimg, Bufa Chemie, Castricum, The Netherlands) 
and different amounts of alb-hep beads. After 2 h of 
incubation at room temperature the precipitated hep- 
arin-toluidine complex or the beads were removed by 
centrifugation. Depletion of the toluidine blue from 
solution was measured at 595 nm. The potentiating 
effect of alb-hep beads (3-5 cm2) on the inhibition of 
thrombin by ATIII was measured using a chromogen- 
ic substrate (S 2238) in an endpoint assay as described 
by Chandler et al.19 Loss of thrombin activity due to 
adsorption of thrombin to the heparinized material 
during the assay did not significantly affect the ob- 
served activity of the heparinized surfaces. Similar 
values for the activity/cm2 were obtained when the 
activity of the heparinized surfaces was determined 
using different amounts of surface per assay. 
Stability of the alb-hep-coated surfaces 
The stability of the albumin or alb-hep conjugate 
coating was investigated using 14C-labeled albumin 
and 14C-labeled alb-hep conjugates. The labeling was 
carried out using 14C-formaldehyde according to the 
procedure as described for the labeling of ATIII. The 
conjugates were freeze dried after dialysis against 
distilled water. The labeled conjugates were co- 
valently immobilized onto the polystyrene beads pre- 
activated with EDC, as described earlier. Control sur- 
faces were prepared by immobilization of 14C-labeled 
albumin or 14C-labeled (Un) alb-hep conjugate with- 
out preactivation of the surface with EDC. The sur- 
face concentration of conjugate or albumin was de- 
termined by measuring the radioactivity on the beads 
and by performing a toluidine blue assay. The stabil- 
ity of the different coatings upon storage of the beads 
in PBS at 5°C was investigated by measuring the ra- 
dioactivity of the supernatant after 10 weeks. The sta- 
bility in a 2% SDS solution in PBS was measured by 
adding 1 mL SDS solution to 100 cm2 of coated beads. 
After 16 h of incubation at room temperature, the 
desorption of conjugate or albumin was examined by 
determining the radioactivity of the supernatant. 
present in a 15-fold excess to a theoreticalmonolayer 
of 0.5 pg/cm2. The reaction mixture was washed 5 
times with PBS pH 7.4 by successive centrifugation 
and resuspendation to remove unbound conjugate. 
The presence of conjugate in the wash fluids was 
AT111 binding kinetics 
Interaction of I4C-labeled ATIII with beads coated 
with different alb-hep conjugates in albumin or 
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plasma solutions was measured at 37°C under stirring 
using an orbital shaker (Ika-Labortechnik, Staufen, 
Germany). ATIII and albumin in PBS pH 7.4 were 
mixed in 1-mL tubes after which alb-hep beads (60 
cm2) were added. The final concentrations of the pro- 
teins were 100 p,g/mL and 27 mg/mL for ATIII and 
albumin, respectively. 14C-ATIII containing plasma 
was diluted with the bead suspension and PBS, re- 
sulting in a 67% (viv) dilution of all proteins present 
and thus in a concentration of ATIII of 100 pg/mL. 
After different incubation times (1-90 min) the beads 
were centrifuged and washed 3 times with PBS. The 
beads were transferred into a scintillation vial, and 
the radioactivity on the beads was determined as de- 
scribed earlier. 
Exchan e of preadsorbed 14C-labeled ATIII by 
unlabekd ATIII 
The exchange of radiolabeled ATIII preadsorbed on 
alb-hep beads was studied by exposing these beads 
to a solution of unlabeled ATIII in PBS. Beads bearing 
a coating of (Un) alb-hep conjugates were incubated 
in a PBS solution containing labeled ATIII (100 pg/ 
mL) and albumin (27 mg/mL) or in a 67% (dv)  plasma 
dilution for 30 min at 37°C. The beads were washed 3 
times with PBS and resuspended in 0.5 mL of a PBS 
solution of unlabeled ATIII, pH 7.4 (500 pg/mL). The 
unlabeled ATIII was from the same source as de- 
scribed for the labeled protein and was purified in the 
same way. Samples of the supernatant were taken 
during incubation at 37°C at different time intervals to 
determine the release of labeled ATIII. 
ATIII binding isotherms 
ATIII binding isotherms were measured to deter- 
mine the affinity of ATIII for the alb-hep surfaces. 
Radiolabeled ATIII in albumin or plasma solutions 
was diluted with PBS in a range from l o p 6  to M. 
The ratio between ATIII and albumin and all the 
other plasma proteins was kept constant. Alb-hep 
beads were added to the ATIII solutions and incu- 
bated for 1 h at 37°C. The beads were washed 3 times 
with PBS and the radioactivity on the beads was mea- 
sured. Control experiments were carried out to de- 
termine the affinity of ATIII for beads having an Alb- 
EDC coating. The ATIII binding isotherms were mod- 
eled using two different equations (i.e., the classical 
Langmuir equation and a summation of two Lang- 
muir equations) to distinguish between ATIII binding 
sites on the surface with different affinities for ATIII. 
An iteration program for curve fitting (MultiFit 1.5, 
Day Computing, Cambridge, U.K.) was used to cal- 
culate the association constants and the maximal 
ATIII surface concentrations for the different iso- 
therms. 
RESULTS 
Purification and characterization of 
I4C-labeled ATIII 
A typical chromatogram of the elution of labeled 
ATIII from a heparin-Sepharose column showed 
three peaks (Fig. 1). From SDS-gel electrophoresis it 
became clear that the first small peak contained IgG, 
probably traces against hepatitis added by the sup- 
plier. The second peak consists of ATIII molecules 
eluted at relatively low ionic strength. After about 150 
mL of eluent was collected, the NaCl concentration 
was increased to 1.8 M. This resulted in a third peak 
consisting of ATIII molecules with a high affinity for 
heparin-Sepharose. Both ATIII peaks gave one single 
band at about 60 kD in a SDS-gel electrophoresis ex- 
periment. 
The radioactivity of the eluent also showed three 
peaks with a pattern corresponding to that shown in 
Fig. 1 (not shown). The third fraction was pooled, 
dialzyed and stored at -30°C. In all further experi- 
ments ATIII from this fraction having a high affinity 
for heparin was used. The column was checked for 
possible overloading, but appeared not to be over- 
loaded. Moreover a similar elution pattern was ob- 
served when unlabeled ATIII was used. To detect any 
change in the affinity of ATIII for the heparin- 
Sepharose upon labeling, labeled ATIII was eluted on 
a heparin-Sepharose column applying a NaCl gradi- 
ent (Fig. 2). An increase in the applied ionic strength 
is followed by elution of a fraction of the bound ATIII. 
An identical elution pattern was observed using un- 
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Figure 1. Elution of I4C-labeled ATIII from heparin- 
Sepharose using a phosphate buffer containing 0.4 and 1.8 
M NaCl, respectively. 
INTERACTION OF ATIII WITH ALR-HEP CONJUGATES 1321 
h s 
1.5 - 0 W 
9 a 1.0 z 
1 .o 
0.5 
0.5 
0.0 0.0 
0 100 200 300 400 500 600 700 
Elution volume (ml) 
Figure 2. Elution profile of 14C-labeled ATIII from hepa- 
rin-Sepharose using a NaCl gradient in phosphate buffer. 
labeled ATIII. When the absorbances at 280 nm of the 
fractions of the labeled ATIII and the unlabeled ATIII 
were plotted against each other, a straight line was 
obtained, indicating no detectable change in the bind- 
ing between ATIII to heparin upon labeling. 
The labeled ATIII was further characterized in a 
thrombin inhibition assay. No statistical difference 
could be observed using labeled and unlabeled ATIII 
in this assay. Possible preferential binding of labeled 
ATIII to an albumin-heparin coated surface was 
checked by mixing unlabeled and labeled ATIII in 
different ratios and exposing these mixtures to alb- 
hep beads. The result is shown in Figure 3. The 
amount of ATIII on the alb-hep surface is propor- 
tional to the ratio between labeled and unlabeled 
ATIII, indicating that no preferential binding oc- 
curred. 
Characterization and stability of the 
alb-hep-coated surfaces 
The characteristics of the alb-hep and control beads 
are reported in Table I. The amount of immobilized 
0 20 40 60  00 100 
C’ 4-ATIII/ATIII (“7’0) 
Figure 3. The surface concentration of I4C-ATIII on poly- 
sytrene beads coated with a lbhep  (HA) conjugates as func- 
tion of the ratio between labeled and unlabeled ATIII in 
solution. 
conjugate according to the toluidine blue assay 
ranged from 0.20 to 0.29 pg/cm2. The surface concen- 
tration of conjugate appeared to be dependent on the 
fraction of heparin in the conjugate. A higher fraction 
of heparin results in a lower surface concentration. 
The biological activity displayed by the heparinized 
beads is dependent on the type of immobilized con- 
jugate: higher ATIII affinities of the surface immobi- 
lized conjugates resulted in a higher activity dis- 
played by the beads. The activity of all control beads 
was approximately zero. The binding of toluidine 
blue to Alb-EDC-beads was negligible. In contrast 
Alb-beads and especially bare polystyrene beads did 
bind significant amounts of tolu‘idine blue. The bind- 
ing of toluidine blue to these control beads was ex- 
pressed in terms of pg Un alb-hep conjugate/cm2. 
The validation of the toluidine blue assay and the 
stability of the alb-hep coating was investigated by 
using I4C-labeled conjugates. The surface concentra- 
tion according to the toluidine blue assay of the la- 
beled conjugates are somewhat lower but in the same 
range as found for the unlabeled conjugates (Table 
11). The values obtained with the tolu’idine blue test 
are in good agreement with the results found by ra- 
dioactivity measurements. Both labeled and unla- 
beled conjugates show a similar trend in surface con- 
centration: a higher heparin content in the alb-hep 
conjugate results in a lower surface concentration. 
The surface concentration of labeled albumin (0.14 
&cm2) is below a monolayer coverage (0.2-0.8 pg/ 
cm2) of protein. 
The majority of the alb-hep conjugates immobi- 
lized using EDC is covalently coupled onto the sur- 
face. Less than 2% of these conjugates was found in 
the supernatant after 10 weeks storage at 5°C in PBS 
or after treatment of these surfaces with a 2% SDS 
solution. Conjugates that are immobilized without 
preactivating the surface with EDC are physically ad- 
sorbed and not covalently attached to the surface. 
These coatings are not stable. 
TABLE I 
Anticoagulant Activity and Surface Concentration of 
Albumin-Heparin Conjugates Coupled onto 
Functionalized Polystyrene Beads 
Type of 
Coating 
albhep (HA) 
a lbhep  (Un) 
albhep (LA) 
Alb 
Alb-EDC 
PS 
HeP 
Content 
of Thromb. 
Conj. Inh. Assay 
w/w (%) (mUh,,/cm2) 
21.5 1.48 2 0.178 
16.5 0.681 k 0.105 
14.5 0.360 t 0.051 
0 -0 
0 -0 
- -0 
Tol. 
Blue Assa Y (PLgconj/cm 1 
0.20 t 0.02 
0.25 2 0.02 
0.29 2 0.01 
0.10‘ ’’ 0.02 
0.01‘ 2 0.01 
0.40“ 2 0.02 
Experimental values: n = 4-7, kSD. 
*Expressed in terms of rJ.g Un a lbhep  conjugateskm’ 
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TABLE I1 
Stability and Surface Concentration of I4C-labeled Albumin-Heparin Conjugates Coupled onto Functionalized 
Polystyrene Beads 
Surface 
Concentration Desorption 
Type of Surface Radioactivity Tol. Blue 2% SDS Storage 
Coating Activation* (Fgicm') ( d c m 2 )  (%I+ (%It 
0.64 f 0.1 0.179 2 ,012 0.18 k .01 1.9 f 0.1 
0.67 f 0.1 alb-hep (Un) Yes 0.201 f ,010 0.22 t .01 1.9 f 0.1 
alb-hep (LA) Yes 0.210 f ,012 0.24 t .01 1.9 f 0.2 0.68 f 0.1 
Alb-EDC Yes 0.194 f ,020 nd 3.0 f 0.3 nd 
albhep (Un) no 0.191 * ,009 0.24 t .01 58.2 i_ 2.5 
Alb no 0.158 2 .012 nd 84.3 t 4.0 
albhep (HA) Yes 
Alb Yes 0.143 f ,007 0.125 t .01 3.3 i 0.2 1.2 f 0.1 
61.1 f 1.2 
8.9 f 0.3 
Experimental values: n = 3-6, fSD. 
Treactivation of the carboxylated polystyrene surfaces with EDC. 
'Desorption of conjugates after 16 h at RT in 270 SDS. 
ZDesorption of conjugates after 10 weeks storage at 5°C in PBS. 
§Expressed in terms of pg Un alb-hep conjugate/cm2. 
ATIII binding kinetics 
The results of the binding kinetics of ATIII are pre- 
sented in Figures 4 and 5. The adsorption of ATIII 
from albumin solutions is fast: more than 80% of the 
total amount of bound ATIII is adsorbed within the 
first minute. The surface concentration of ATIII 
reached a constant value after about 5-10 min. The 
plateau values of ATIII adsorbed on the different sur- 
faces correlate with the affinity of the immobilized 
conjugates for ATIII. The plateau values are 3.1, 4.1, 
and 7.5 ng/cm2 for beads containing LA, Un, and HA 
qlb-hep conjugates, respectively. 
ATIII adsorption from plasma solutions shows a 
high initial ATIII surface concentration after one 
minute of incubation, followed by a slight decrease at 
longer incubation times (Fig. 5). A constant surface 
concentration is reached after about 5-10 min of in- 
I 
0 20  4 0  6 0  80 
time (min) 
Figure 4. Kinetics of the binding of ATIII from an albumin 
(26.7 mg/mL)-ATIII(100 pg/mL) mixture in PBS onto poly- 
styrene beads containing different alb-hep conjugates. (W) 
HA alb-hep conjugates, (A) Un a lbhep  conjugates, (0) LA 
alb-hep conjugates. 
cubation. The plateau values for AT111 adsorbed from 
plasma solutions are 2-3 times less than the values 
obtained from corresponding experiments where 
ATIII is adsorbed from albumin solutions. 
Exchange of preadsorbed l4C-labeIed ATIII by 
unlabeled ATIII 
The release of labeled ATIII molecules from beads 
that were preincubated in 14C-ATIII containing 
plasma or in alb~mini'~C-ATII1 solutions is shown in 
Figure 6. After contacting the beads with a solution of 
unlabeled ATIII in PBS, the amount of labeled ATIII 
at the surface starts to decrease. A constant value is 
reached after approximately 10 min. About 70% of 
the initial amount of labeled ATIII molecules is re- 
leased independent of the medium used for preincu- 
bation. 
0 20 4 0  60 80  100 
time (min) 
Figure 5. Kinetics of the binding of ATIII (100 pg/mL) 
from a 67% plasma dilution with PBS onto polystyrene 
beads containing different alb-hep conjugates. (W) HA alb- 
hep conjugates, (A) Un alb-hep conjugates, (0) LA alb- 
hep conjugates. 
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Figure 6. Decrease of the surface concentration of '*C- 
ATIII adsorbed on polystyrene beads containing immobi- 
lized Un alb-hep conjugates after contacting the surface 
(100 cm') with a solution of unlabeled ATIII in PBS (500 
bg/ML) for different time periods. (0) preadsorbing from 
an albumin-AT111 solution, (A) preadsorbing from a plasma 
dilution. 
ATIII binding isotherms 
ATIII-binding isotherms obtained using albumin 
solutions do not reach plateau values under the ex- 
perimental conditions used (Fig. 7). Binding iso- 
therms using plasma solutions show a high affinity 
character and seem to reach a plateau value at equi- 
librium concentrations of ATIII exceeding l o p 6  M in 
solution (Fig. 8). The isotherms for the binding of 
ATIII onto the various surfaces were fitted with the 
classical Langmuir equation (1). An iteration program 
for curve fitting was used to calculate both the asso- 
ciation constant and the maximal ATIII surface con- 
centration. 
" I  
O.Oe+O 1 .Oe-6 2.0e-6 3.0e-6 
Ceq (mole/l) 
Figure 7. Isotherms for the binding of ATIII onto polysty- 
rene beads coated with different alb-hep conjugates or 
Alb-EDC. (M) HA alb-hep conjugates, (A) Un alb-hep con- 
jugates, (0) LA alb-hep conjugates, (0) Alb-EDC. ATIII 
binding took place from albumin-AT111 mixtures in PBS, 
pH 7.4 at 37°C. C,, is the equilibrium concentration of ATIII 
in solution. 
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Figure 8. Isotherms for the binding of ATIII onto polysty- 
rene beads coated with different alb-hep conjugates or 
Alb-EDC. (M) HA alb-hep conjugates, (A) Un alb-hep con- 
jugates, (0) LA alb-hep conjugates, (0) Alb-EDC. ATIII 
binding took place from plasma dilutions with PBS, pH 7.4 
at 37°C. C,, is the equilibrium concentration of ATIII in 
solution. 
where: C, = ATIII surface concentration 
(ng/cm2) 
C,, = maximal ATIII surface 
concentration (ng/cm2) 
K = binding constant (L/mole) 
C,, 
solution (mole/L) 
= ATIII equilibrium concentration in 
Scatchard plots were obtained using values for 
C,, calculated with the curve-fitting program. The 
slopes of these plots, based on the isotherms for ATIII 
using albumin solutions, change with the fraction of 
bound protein (Fig. 9). Scatchard plots based on iso- 
therms obtained using plasma dilutions result in 
straight lines with a steep slope (Fig. 10). Small devi- 
ations from these lines are observed when the surface 
coverage is very low and when C,/C,,,, approaches 
1. The adsorption of ATIII from plasma or albumin 
solutions onto control beads containing an Alb-EDC 
4.0e+6 - 
(I) - 
E 3.0e+6 > 
v 
2.0e+6 
Y 
5 
1 .Oe+6 
O.Oe+O 
7 
0 
0.0 0.2 0.4 0.6 0.8 1.0 
V 
Figure 9. Scatchard plots for the binding of ATIII from 
albumin-AT111 mixtures in PBS onto polystyrene beads 
containing different a lbhep conjugates. (n) HA alb-hep 
conjugates, (A) Un albhep conjugates, (0) LA alb-hep 
conjugates. v = Cs/Csmax. 
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Figure 10. Scatchard plots for the binding of ATIII from 
plasma dilutions onto polystyrene beads containing differ- 
ent a l b h e p  conjugates. (0) HA alb-hep conjugates, (A) Un 
alb-hep conjugates, (0) LA alb-hep conjugates. u = C,/ 
Csrnar 
coating was very small (Figs. 7 and 8). In this case no 
Langmuir isotherms of ATIII adsorption could be es- 
tablished. 
The isotherms of ATIII using albumin solutions 
also were fitted with a summation of two Langmuir 
equations to discriminate between binding sites on 
the surface with different binding constants for ATIII, 
Equation (2). Each term describes a Langmuirian 
binding of ATIII to a set of binding sites with a certain 
affinity for ATIII. These two sets of sites are hence- 
forth referred to as type 1 and type 2 binding sites. In 
this case four variables were used in the iteration pro- 
gram to fit the isotherms. These variables are two 
binding constants and two maximal surface concen- 
trations for the two different sets of binding sites. A 
simplification of Equation (2) was used for the iso- 
therms obtained using plasma dilutions. The contri- 
bution of the second Langmuir equation in Equation 
(2) using plasma dilutions appeared to be very small. 
No maximal surface concentration could be obtained 
with the iteration program. Therefore a term that de- 
scribes a proportional increase of the ATIII surface 
concentration with an increasing equilibrium concen- 
tration of ATIII in solution is used [Eq. ( 3 ) ] .  
(3) 
where: CSma,, =. maximal ATIII surface 
concentration on type "1''-binding 
site (ng/cm2) 
= ATIII binding constant to type 
"1"-binding site (limole 
= constant (ng Limole cm ) 
K ,  
A 3 
Table I11 shows the results of the modeling of the 
ATIII-binding isotherms with Equations (1) and (2) or 
(3) in terms of the residual sum of squares (RSS) and the 
calculated values for the different binding constants. 
From the RSS values in Table I11 it is clear that a 
summation of two equations results in a better de- 
scription of the isotherms than a single Langmuir 
equation. This is most pronounced for the binding of 
ATIII from albumin solutions onto the different alb- 
hep surfaces. When Equation (2) is used, two average 
binding constants are obtained for the two sets of 
binding sites for ATIII. K ,  describes the binding of 
ATIII to binding sites with a rather high affinity for 
ATIII, while K ,  accounts for binding of ATIII to sites 
with a lower affinity for the protein. The values for 
the constant A are small, which indicates that there is 
only a minor contribution of the binding of ATIII 
from plasma solutions to low-affinity binding sites on 
the surface. 
The K ,  binding constant for the binding of ATIII 
adsorbed from albumin solutions to LA alb-hep 
beads is rather small. In this case the division into 
"high' and "low" affinity binding sites by the itera- 
TABLE I11 
Modeling of the ATIII Binding Isotherms, Binding Constants and Residual Sum of Squares 
Equation (1) Equation (2) 
Type of Incubation K x lo6 K, x lob K, x 106 
Coating Medium (Limole) RSS" (Limole) (Limole) RSS" 
alb-hep (HA) alb 
alb-hep (Un) alb 
alb-hep (LA) alb 
1.55 1.2818 10.5 0.377 0.0524 
1.11 0.4273 8.96 0.332 0.0373 
1.35 0.1909 4.85 0.130 0.0197 
Equation (1) Equation (3) 
Type of Incubation K x lo6 K ,  x lo6 A x lo6 
Coating Medium (Limole) RSS" (Limole) (ngiM cm2) RSS" 
alb-hep (HA) Plasma 7.10 0.0077 7.78 0.066 0.0058 
all>-hep (Un) Plasma 7.84 0.0043 8.41 0.076 0.0040 
alb-hep (LA) Plasma 6.60 0.0037 9.12 0.022 0.0009 
"Residual sum of squares. 
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tion program results in a K, value of 4.85 x lo6 M-I, 
which is smaller than the other K, binding constants. 
A consequence of this fact would be that the maximal 
ATIII surface concentration of high affinity binding 
sites on LA alb-hep beads is higher than on beads 
bearing Un alb-hep conjugates, which is very un- 
likely. An average value of K, using the data for both 
media was calculated in which the K, value of LA 
alb-hep beads was not taken into account. This av- 
erage K ,  value of 9 x lo6 L/mol was further used in 
Equations (2) and ( 3 )  to compare the maximal 
amounts of available binding sites on the different 
alb-hep surfaces in the two incubation media. The 
results are given in Table IV and in Figures 11 and 12. 
The RSS values were not, or were minimally, in- 
creased when a fixed value of 9 X lo6 L/mol for K, 
was used compared to the results obtained when K, 
was variable (Table 111). The average value of the 
binding constant for the interaction of ATIII using 
albumin solutions with sites having a relatively low 
affinity for ATIII is 0.33 x lo6 L/mol. The maximal 
ATIII surface concentrations for the two sets of bind- 
ing sites using albumin solutions (Cs,,,l and CsmaXz) 
are both dependent on the type of immobilized con- 
jugate. More ATIII was bound to both sets of sites 
when the affinity of the immobilized conjugate for 
ATIII increases (HA > Un > LA). When ATIII is ad- 
sorbed from plasma dilutions, a similar trend is ob- 
served for CSmax1. Comparison of the values of CSmax1 
for the binding of ATIII from plasma and albumin- 
ATIII solutions reveals that the values of C,,, for 
the binding of ATIII from plasma solutions are about 
30% lower than the corresponding values for the 
binding from albumin solutions. 
Figure 11 shows the results of the modeling for the 
isotherm obtained with albumin solutions onto sur- 
faces containing HA alb-hep conjugate using Equa- 
h el . g 6  
rn 
C 
v 
3 4  
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Figure 11. Modeling of the binding of ATIII from albu- 
min-AT111 solutions onto polystyrene beads coated with 
HA a l b h e p  conjugates using Equation 2. (A) represents 
the fit through the data points. (B) and (C) represent the 
Langmuirian binding of ATIII to two different sets of bind- 
ing sites on the surface having a high (C) or a low (B) 
affinity for ATIII. 
tion (2) and K, fixed at 9 x lo6 Limol. Besides the fit 
through the data points, curves are drawn using the 
data in Table IV. The curve fitted through the exper- 
imental data points is the summation of the two 
Langmuir isotherms with a high and a low binding 
constant for ATIII. Figure 12 shows the result of the 
modeling using Equation (3) and a fixed K, value of 9 
x lo6 Limo1 for the binding of ATIII onto HA immo- 
bilized albhep conjugates using plasma dilutions. In 
this case the curves represent the two terms in Equa- 
tions (3); the Langmuir equation and a proportional 
increase of C, with Ceq, respectively. The most strik- 
ing difference between Figures 11 and 12 is the con- 
tribution of the second term, which describes the 
binding of ATIII to binding sites with a rather low 
affinity for ATIII. It becomes clear that the contribu- 
tion of the binding of ATIII to binding sites with a low 
TABLE IV 
Modeling of the ATIII Binding Isotherms with a Summation of Two Langmuir Equations and a Fixed Kl Value 
Incubation C S m a X l  K, x lo6 Csrnax2 
Type of Coating Medium (ng/cm2) (Limole) (ng/cm2) RSS* 
Equation 2 
alb-hep (HA) 
alb-hep (Un) 
alb-hep (LA) 
alb 
alb 
alb 
2.91 
1.42 
1.05 
0.330 
0.333 
0.338 
9.88 0.0554 
7.00 0.0373 
4.23 0.0264 
Equation 3 
Type of Coating Medium (ng/cm2) (ng/M cm2) (ng/cm2) RSS" 
Incubation C s m a x l  A x lo6 C S m a X 2  
albhep (HA) Plasma 2.09 0.137 - 0.0095 
alb-hep (Un) Plasma 0.950 0.038 - 0.0042 
alb-hep (LA) Plasma 0.655 0.074 - 0.0009 
K, = 9 . W  LimoI. 
*RSS = residual sum of squares. 
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Figure 12. Modeling of the binding of ATIII from plasma 
dilutions onto polystyrene beads coated with HA alb-hep 
conjugates using Equation 3. (A) represents the fit through 
the data points. (B) and (C) represent the Langmuirian 
binding of ATIII to two different sets of binding sites on the 
surface having a high (C) or low (B) affinity for ATIII. 
affinity for ATIII to the total amount of bound ATIII is 
much smaller when ATIII is adsorbed from plasma 
dilutions than when albumin solutions are used. 
DISCUSSION 
In this study I4C-labeled and purified ATIII was 
used to investigate in detail the different interactions 
of ATIII with a heparinized surface. The labeled ATIII 
showed no preferential binding over unlabeled ATIII 
for binding to polystyrene beads containing HA alb- 
hep conjugates and therefore was regarded as biolog- 
ically active in binding to heparin. 
The immobilization of alb-hep conjugates on car- 
boxylated polystyrene beads by means of preactiva- 
tion of the surface with EDC resulted in a stable coat- 
ing with a surface concentration of 0.2-0.3 pg/cm2. 
The heparin activity per surface area was dependent 
on the type of the immobilized conjugate. The anti- 
coagulant activity of the surfaces increased in the or- 
der LA, Un, HA while the surface concentration of 
conjugate decreased in the same order. The differ- 
ences in surface concentration (0.20, 0.25, and 0.29 
pg/cm2 for HA, Un, and LA alb-hep surfaces, respec- 
tively) may be explained by the occurrence of electro- 
static repulsion during coupling. An increased hepa- 
rin content in the alb-hep conjugates results in an 
increased repulsion during coupling, first between 
negatively charged conjugates in solution and bare 
spots on the negatively charged surface, and, second, 
between conjugates in solution and spots already 
covered with conjugates. This leads to a lower surface 
concentration for conjugates having a higher heparin 
content. The depletion of the toluidine blue solution 
by bare polystyrene beads can be explained by the 
anionic character of the polymer surface. Coloring of 
beads containing a coating of albumin (0.14 pg/cm2) is 
probably caused by binding of toluidine blue to bare 
spots on the surface. The toluidine blue assay to de- 
termine the surface concentration of alb-hep conju- 
gates therefore can be applied only with polystyrene 
beads having a monolayer coverage of conjugate on 
the surface. 
ATIII binding kinetics 
The binding of ATIII to alb-hep surfaces was very 
fast. Within a few minutes a plateau value was 
reached. When ATIII was adsorbed from a 67% 
plasma dilution in PBS, an initial increase of the ATIII 
surface concentration was followed by a slight de- 
crease. This phenomenon may be explained by the 
”Vroman” The “Vroman” effect involves 
the complex change of the protein composition on a 
solid surface as a function of time, due to differences 
in protein concentration, adsorption energy, and dif- 
fusion coefficients. In time a fraction of the initially 
bound ATIII, a relatively small protein of 58.2 kD, is 
desorbed by other plasma proteins. Desorption of ini- 
tially bound ATIII molecules in combination with di- 
rect competition of ATIII with other plasma proteins 
for binding sites at the surface results in plateau val- 
ues of ATIII that are about 2-3 times lower using 
plasma dilutions than the surface concentrations 
found for AT111 adsorbed from albumin solutions. 
The capacity of the alb-hep surfaces to bind ATIII 
from plasma ranged from 0.8 to 2.2 ng/cm2, which is 
only a few percent of a theoretical mono!ayer of 
ATIII. These values correspond well with values for 
the binding of ATIII from plasma to different poly- 
methacrylate surfaces coated sequentially with albu- 
min and heparin as reported by Lindon et al.5 
Only a very small fraction of the immobilized hep- 
arin is able to bind ATIII. The ATIII surface concen- 
trations, combined with the surface concentration of 
(HA) alb-hep conjugates reported in Table I, result in 
an alb-hep/ATIII ratio (mole/mole) on the surface of 
2O:l to 65:l using albumin or plasma solutions, re- 
spectively. The low ATIII binding capacity of the alb- 
hep surfaces may be attributed to the immobilization 
procedure of heparin. Heparin is covalently attached 
to the albumin in the presence of an excess of EDC. 
This may lead to more than one covalent bond be- 
tween heparin and the protein, which would result in 
chemical modification of the heparin and in a reduced 
segmental flexibility that would affect the binding of 
ATIII. A further decrease in the ATIII binding capac- 
ity of the alb-hep conjugates can be expected after 
coupling onto the polystyrene surface. 
The ATIII binding capacity and the anticoagulant 
activity displayed by the heparinized surfaces are a 
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function of the type of immobilized conjugate; hence 
a correlation exists between the binding capacity of 
the surfaces for ATIII and their biological activity. 
Similar observations were made by Hennink et al., 
who studied the interaction of ATIII with polystyrene 
surfaces preadsorbed with different alb-hep conju- 
gates. 16,25 
ATIII binding isotherms 
The ATIII binding isotherms were modeled using 
the Langmuir equation. One of the conditions for the 
use of a Langmuir equation is reversibility of binding. 
Although the interaction between heparin and ATIII 
can be regarded as a kind of ligand-receptor binding, 
about 30% of initially surface bound (labeled) ATIII 
could not be exchanged by unlabeled ATIII. Thus 
care has to be taken in the interpretation of the results 
of the modeling because not all of the conditions are 
met for using the Langmuir equation. Scatchard plots 
of the isotherms obtained from the adsorption of 
ATIII from albumin solutions showed a concave up 
plot. This may be explained either by the presence of 
a variety of binding sites on the surfaces having dif- 
ferent binding constants for ATIII or by lateral repul- 
sion between surface-bound ATIII molecules. The lat- 
ter is not very likely because of the low surface occu- 
pancy of ATIII. The presence of different binding 
sites for ATIII may be explained by the heterogeneity 
of the immobilized heparin, the influence of the im- 
mobilization procedure on the mobility of heparin, 
and the accessibility of heparin for ATIII. These find- 
ings can be compared with the binding of ATIII on 
heparin-Sepharose at different ionic strengths. Fig- 
ure 2 shows that heparin-Sepharose contains binding 
sites from which ATIII could be eluted at different 
ionic strengths. This also may be explained by the 
presence of binding sites with different affinity for 
ATIII. Scatchard plots based on isotherms obtained 
from the adsorption of ATIII from plasma dilutions 
show straight lines, with only small deviations at low 
and high surface occupancy by ATIII. This indicates 
that ATIII in the presence of plasma proteins is bound 
to binding sites with an almost uniform affinity for 
ATIII. The binding constant is rather high, 7 X lo6 
Limol. In contrast, the average binding constant for 
the binding of ATIII using albumin solutions onto the 
same alb-hep coated surfaces is +1 x lo6 L/mol. 
These differences may be explained by the presence 
of high and low affinity binding sites for ATIII to- 
gether with binding of other plasma proteins onto the 
heparinized surface. Plasma proteins will occupy po- 
tential ATIII binding sites resulting in a lower surface 
occupancy of ATIII. Only binding sites on the surface 
with a high affinity for ATIII retain their capacity to 
bind ATIII in the presence of adsorbed plasma pro- 
teins. 
ATIII binding isotherms for the adsorption of ATIII 
from PBS solutions containing albumin and ATIII also 
were modeled using a summation of two Langmuir 
equations’ Equation (2). Equation (3) was used to de- 
scribe the ATIII adsorption from plasma dilutions. 
The binding constant that describes the binding of 
ATIII to binding sites with a rather high affinity for 
ATIII (K,) was about 9 X lo6 L/mol. This interaction 
may be regarded as the specific interaction between 
heparin, containing the pentasaccharide sequence, 
and ATIII. The value for K ,  comes close to literature 
values of *1 X lo7 L/mol for binding of ATIII from 
plasma heparin-Sepharose.26 The binding constant 
for the binding of ATIII to binding sites with a low 
affinity for ATIII was about 0.3 X lo6 L/mol when 
albumin solutions were used. A similar value was 
found by Fougnot et al. for the binding of ATIII from 
buffer solutions to sulphonated polystyrene and sul- 
phonate-glutamic acid sulphamide polystyrene, 
which are regarded as “heparin-like” surfaces. 27 The 
maximal binding capacity of nonspecific ATIII bind- 
ing sites (Csmax2) on alb-hep surfaces increases with 
increasing affinity of the immobilized conjugates for 
ATIII. Thus the binding of ATIII from albumin solu- 
tions to binding sites with a rather low affinity for 
ATIII can be attributed to nonspecific interaction be- 
tween ATIII and the immobilized heparin. There is 
some adsorption of ATIII onto the Alb-EDC beads 
using albumin solutions. A small amount of the sur- 
face bound ATIII on the alb-hep surface therefore 
probably is adsorbed to sites not covered with hepa- 
rin. 
The nonspecific binding of ATIII to the HA alb-hep 
surfaces using plasma solutions is very small (Fig. 12) 
and is comparable to the adsorption of ATIII from 
plasma solutions to the Alb-EDC control surface (Fig. 
8). These data suggest that nonspecific binding of 
ATIII on alb-hep surfaces in the presence of plasma 
proteins is low and not mediated by immobilized 
heparin on the surface. 
The number of specific binding sites (Csmaxl) that 
can bind ATIII in the presence of plasma proteins is 
about 30% less than those that can bind ATIII only in 
the presence of albumin. This must be ascribed to the 
plasma proteins on the heparinized surface partly 
neutraIizing the interaction between ATIII and high 
affinity binding sites of the immobilized heparin. 
In summary, the binding of ATIII to nonspecific 
binding sites on the surface is almost completely in- 
hibited in the presence of plasma proteins and the 
interaction behveen ATIII and surface-immobilized 
heparin containing specific ATIII binding sites is in- 
hibited to some extent. In this study a fixed amount 
of 200 FL (diluted) plasma is contacted with 60 cm2 
heparinized surface. During incubation a depletion of 
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proteins that influence the ATIII-surface interaction 
may occur. It therefore can be speculated that the 
inhibition of the specific interaction between ATIII 
and surface-immobilized heparin may be higher 
when the surface is contacted with an excess of 
plasma. 
Two different processes may contribute to the neu- 
tralization effect. First, the outcome of the competi- 
tion of ATIII with other heparin binding proteins for 
the surface-immobilized heparin depends on the af- 
finities of the involved proteins for heparin and their 
relative concentrations. The affinities of heparin- 
binding proteins such as HRGP and vitronectin for 
heparin at physiological pH and ionic strength are 
both high (?los L / m ~ l e ) , ~ , ' ~  whereas the affinity of 
ATIII for heparin is *lo7 L/mole.22,28 The concentra- 
tions of heparin-binding proteins in this study are 
unknown because the depletion of ATIII from plasma 
using heparin-Sepharose probably also resulted in 
decreased concentrations of these proteins. The neu- 
tralization of the ATIII binding to the surface-im- 
mobilized heparin thus may be even larger at physi- 
ological concentrations of heparin-binding proteins. 
A second process that may influence the binding of 
ATIII is nonspecific adsorption of plasma proteins on 
the surface. For instance, adsorption of plasma pro- 
teins onto sites at the surface not covered with hep- 
arin may have an effect on the accessibility of heparin 
for ATIII. Further, it may be speculated that the al- 
bumin molecule is denatured during preparation and 
immobilization of the conjugate. Adsorption of 
plasma proteins onto the albumin moiety of the con- 
jugate therefore cannot be excluded. 
The identification of the proteins involved and the 
impact of the neutralization of the ATIII binding on 
the anticoagulant activity displayed by the surface- 
immobilized heparin currently are being investi- 
gated. 
CONCLUSIONS 
Covalent coupling of alb-hep conjugates onto car- 
boxylated polystyrene surfaces resulted in a stable 
coating that displayed anticoagulant activity. The in- 
teraction between ATIII and these alb-hep surfaces 
either in the presence of albumin or in plasma was 
investigated. It was demonstrated that three different 
interactions played a role in the binding of ATIII onto 
the heparinized surfaces. First, ATIII could bind with 
high affinity to immobilized heparin containing spe- 
cific ATIII binding sites. Second, ATIII was bound to 
the heparinized surface mediated by nonspecific in- 
teractions between ATIII and the immobilized hepa- 
rin. Third, a small fraction of the surface bound ATIII 
molecules probably was adsorbed to sites on the hep- 
arinized surface not covered with heparin. Plasma 
proteins were able to desorb initially bound ATIII, 
and they inhibited, to some extent, specific and non- 
specific interactions between ATIII and the immobi- 
lized heparin. Binding of ATIII to nonspecific binding 
sites having a rather low affinity for ATIII was almost 
completely inhibited in the presence of plasma pro- 
teins. Binding of ATIII to immobilized heparin con- 
taining specific ATIII binding sites with a high affinity 
for ATIII decreased 30% in the presence of plasma 
proteins in comparison with the binding of ATIII 
from albumin containing PBS. This reduction in ATIII 
binding is probably higher when more plasma is ap- 
plied per surface area and when the plasma contains 
physiological concentrations of heparin-binding pro- 
teins. 
It is concluded that the accessibility of immobilized 
heparin for ATIII is decreased by adsorption of 
plasma proteins onto the heparinized surface and/or 
by competition of ATIII with other heparin-binding 
proteins for the surface-immobilized heparin. The 
neutralization of the ATIII binding to surface-im- 
mobilized heparin in plasma may affect the biological 
activity and performance of the heparinized material 
when a correlation exists between the binding of 
ATIII to the heparinized surface and the anticoagu- 
lant activity displayed by the surface in plasma. 
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